The myeloproliferative neoplasms including the eosinophilia-related myeloproliferations associated with tyrosine kinase mutations: changes and issues in classification and diagnosis criteria

被引:3
作者
Anastasi, John [1 ]
机构
[1] Univ Chicago, Hematopathol Sect, Dept Pathol, Chicago, IL 60637 USA
关键词
Myeloproliferative neoplasms; Tyrosine kinase; Chronic myelogenous leukemia; Eosinophilia; Polycythemia vera; Essential thrombocythemia; Primary myelofibrosis; Mast cell disease; JAK2 V617F MUTATION; CHRONIC MYELOID-LEUKEMIA; ESSENTIAL THROMBOCYTHEMIA; POLYCYTHEMIA-VERA; IMATINIB MESYLATE; PRIMARY MYELOFIBROSIS; REFRACTORY-ANEMIA; DISORDERS; THERAPY; TRANSLOCATIONS;
D O I
10.1053/j.semdp.2011.07.001
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
The classification and diagnostic criteria of the myeloproliferative neoplasms have changed significantly in the 2008 World Health Organization monograph on the classification of hematologic malignancies. Many of the changes arose from the findings that the different malignancies are associated with abnormal cell signaling because of translocations or mutations in genes for protein tryosine kinases involved in the normal growth and regulation of hematopoietic cells. These include ABL1, PDGFRA, PDGFRB, FGFR1, JAK2, MPL, and KIT. The new classification attempts to reflect the related molecular pathogenesis of the different entities and incorporates the identification of the molecular defects into the diagnostic criteria for some of the individual diseases. Issues concerning the new classification are discussed, and the new diagnostic criteria are reviewed and commented upon. (C) 2011 Elsevier Inc. All rights reserved.
引用
收藏
页码:304 / 313
页数:10
相关论文
共 46 条
  • [1] [Anonymous], CELL
  • [2] Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta
    Apperley, JF
    Gardembas, M
    Melo, JV
    Russell-Jones, R
    Bain, BJ
    Baxter, J
    Chase, A
    Chessells, JM
    Colombat, M
    Dearden, CE
    Dimitrijevic, S
    Mahon, FX
    Marin, D
    Nikolova, Z
    Olavarria, E
    Silberman, S
    Schultheis, B
    Cross, NCP
    Goldman, JM
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (07) : 481 - 487
  • [3] Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
    Baxter, EJ
    Scott, LM
    Campbell, PJ
    East, C
    Fourouclas, N
    Swanton, S
    Vassiliou, GS
    Bench, AJ
    Boyd, EM
    Curtin, N
    Scott, MA
    Erber, WN
    Green, AR
    [J]. LANCET, 2005, 365 (9464) : 1054 - 1061
  • [4] Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders
    Bellanne-Chantelot, Christine
    Chaumarel, Isabelle
    Labopin, Myriarn
    Bellanger, Florence
    Barbu, Veronique
    De Toma, Claudia
    Delhommeau, Frangois
    Casadevall, Nicole
    Vainchenker, William
    Thomas, Gilles
    Najman, Albert
    [J]. BLOOD, 2006, 108 (01) : 346 - 352
  • [5] Mutation of JAK2 in the myeloproliferative disorders:: timing, clonality studies, cytogenetic associations, and role in leukemic transformation
    Campbell, Peter J.
    Baxter, E. Joanna
    Beer, Philip A.
    Scott, Linda M.
    Bench, Anthony J.
    Huntly, Brian J. P.
    Erber, Wendy N.
    Kusec, Rajko
    Larsen, Thomas Stauffer
    Giraudier, Stephane
    Le Bousse-Kerdiles, Marie-Caroline
    Griesshammer, Martin
    Reilly, John T.
    Cheung, Betty Y.
    Harrison, Claire N.
    Green, Anthony R.
    [J]. BLOOD, 2006, 108 (10) : 3548 - 3555
  • [6] Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status:: a prospective study
    Campbell, PJ
    Scott, LM
    Buck, G
    Wheatley, K
    East, CL
    Marsden, JT
    Duffy, A
    Boyd, EM
    Bench, AJ
    Scott, MA
    Vassiliou, GS
    Milligan, DW
    Smith, SR
    Erber, WN
    Bareford, D
    Wilkins, BS
    Reilly, JT
    Harrison, CN
    Green, AR
    [J]. LANCET, 2005, 366 (9501) : 1945 - 1953
  • [7] Leukocytosis and risk stratification assessment in essential thrombocythemia
    Carobbio, Alessandra
    Antonioli, Elisabetta
    Guglielmelli, Paola
    Vannucchi, Alessandro M.
    Delaini, Federica
    Guerini, Vittoria
    Finazzi, Guido
    Rambaldi, Alessandro
    Barbui, Tiziano
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (16) : 2732 - 2736
  • [8] The JAK2 V617F mutation is rare in RARS but common in RARS-T
    Ceesay, M. M.
    Lea, N. C.
    Ingram, W.
    Westwood, N. B.
    Gaken, J.
    Mohamedali, A.
    Cervera, J.
    Germing, U.
    Gallermann, N.
    Giagounidis, A.
    Garcia-Casado, Z.
    Sanz, G.
    Mufti, G. J.
    [J]. LEUKEMIA, 2006, 20 (11) : 2060 - 2061
  • [9] A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome
    Cools, J
    DeAngelo, DJ
    Gotlib, J
    Stover, EH
    Legare, RD
    Cortes, J
    Kutok, J
    Clark, J
    Galinsky, I
    Griffin, JD
    Cross, NCP
    Tefferi, A
    Malone, J
    Alam, R
    Schrier, SL
    Schmid, J
    Rose, M
    Vandenberghe, P
    Verhoef, G
    Boogaerts, M
    Wlodarska, I
    Kantarjian, H
    Marynen, P
    Coutre, SE
    Stone, R
    Gilliland, DG
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (13) : 1201 - 1214
  • [10] WHO-defined chronic neutrophilic leukemia: a long-term analysis of 12 cases and a critical review of the literature
    Elliott, MA
    Hanson, CA
    Dewald, GW
    Smoley, SA
    Lasho, TL
    Tefferi, A
    [J]. LEUKEMIA, 2005, 19 (02) : 313 - 317